4th May 2026
Aegros has appointed Dr Paul MacLeman BVSc MBA GAICD to its Board as a Non-Executive Director, bringing deep expertise in biopharmaceutical development, finance, ASX-listed company governance, and specialty biologics commercialisation.
Dr MacLeman’s career spans executive leadership across multiple ASX, CSE and NASDAQ listed and private life sciences companies. He served as SVP Agenix (ASX:AGX) an antibody manufacturer, CEO of Genetic Technologies Ltd (ASX:GTG; NASDAQ:GENE), Managing Director of IDT Australia (ASX:IDT) – one of Australia’s leading Speciality Pharmaceutical manufacturers – Director of Nextleaf Ltd (CSE:OILS), and Executive Chair of Island Pharmaceuticals (ASX:ILA). He currently chairs AdAlta Limited (ASX:1AD), a clinical-stage company developing i-body immunobiologics and cell therapies. He drove the IPOs of Adalta, Nextleaf and Island, and an upgrade of the GTG NASDAQ listing.
Dr MacLeman’s background in pharmaceutical and biologics manufacturing is particularly relevant to Aegros’s development of scalable plasma fractionation capability through the Haemafrac® process.
“Plasma-derived medicines are among the most complex biologics to manufacture at scale, and Australia has a real opportunity to build sovereign capability at scale in this space,” said Dr MacLeman. “Aegros has the technology and the team to be a meaningful part of that solution.”
Damian Thornton, CEO and Managing Director of Aegros, said, “We are delighted to welcome Dr MacLeman at this pivotal stage in Aegros’ evolution. As we accelerate toward GMP licensing and the commencement of commercial operations, his deep experience across biopharmaceutical development, manufacturing, and listed company leadership adds significant strategic and governance strength to the Board. Paul’s track record in scaling life sciences businesses and navigating global markets will be invaluable as Aegros positions itself as a leading player in the PDMP sector.”
Dr MacLeman holds a BVSc, an MBA, Grad Dip Tech Mgt, Grad Cert Eng and is a Graduate of the AICD. He serves on multiple life sciences boards and advisory bodies.
